Marika Rasschaert1, Silke Helsen2, Christian Rolfo3, Ilse Van Brussel4, Jo Ravelingien4, Marc Peeters3,5. 1. Department of Oncology, Multidisciplinary Oncological Center Antwerp, MOCA, University Hospital Antwerp, Wilrijkstraat 10, 2650, Edegem, Belgium. marika.rasschaert@uza.be. 2. Department of Ophtalmology, University Hospital Antwerp, Wilrijkstraat 10, 2650, Edegem, Belgium. 3. Department of Oncology, Multidisciplinary Oncological Center Antwerp, MOCA, University Hospital Antwerp, Wilrijkstraat 10, 2650, Edegem, Belgium. 4. Remedus BVBA, Boomsesteenweg 44, 2630, Aartselaar, Belgium. 5. University of Antwerp, Prinsstraat 13, 2000, Antwerp, Belgium.
Abstract
BACKGROUND: The introduction of oral anti-cancer agents provides a convenient administration route for chronic cancer treatment to outpatients. Health information technology through web-based applications or other electronic tools can offer a platform to improve treatment compliance, symptom management, and patient-provider communication. PURPOSE: The purposes of this study were to test the feasibility and clinical utility of an electronic self-report device (RemeCoach) for patients or their caregivers and to register and prospectively evaluate the quality of data generated. PATIENTS AND METHODS: Patients using Teysuno® (S-1) for advanced gastrointestinal carcinoma used a pre-programmed device in order to register compliance to treatment and six clinical parameters. Real-time data were collected onto a central platform, which processed the data by an algorithm. This algorithm stratified the data into different grades based on the Common Terminology Criteria for Adverse Events (CTCAE v4.0). RESULTS: From December 2013 to March 2014, 11 patients (5 men, 6 women) were enrolled. Compliance to the device was high, six patients (55 %) registered timely intake of medication (demonstrating >95 % treatment compliance). Agreement between patients' and clinicians' reported toxicity was substantial for nausea, but discrepant for fatigue, hand-foot syndrome, and mucositis. CONCLUSION: The use of an interactive self-report tool is feasible, reliable, and acceptable to outpatients. The RemeCoach and the algorithm devised will be further developed as an interactive patient-reported outcome (PRO) system, to improve early detection of side effects in an outpatient setting. Further studies are needed to confirm these data and to explore the relationship between optimal patient support and efficacy of treatment.
BACKGROUND: The introduction of oral anti-cancer agents provides a convenient administration route for chronic cancer treatment to outpatients. Health information technology through web-based applications or other electronic tools can offer a platform to improve treatment compliance, symptom management, and patient-provider communication. PURPOSE: The purposes of this study were to test the feasibility and clinical utility of an electronic self-report device (RemeCoach) for patients or their caregivers and to register and prospectively evaluate the quality of data generated. PATIENTS AND METHODS: Patients using Teysuno® (S-1) for advanced gastrointestinal carcinoma used a pre-programmed device in order to register compliance to treatment and six clinical parameters. Real-time data were collected onto a central platform, which processed the data by an algorithm. This algorithm stratified the data into different grades based on the Common Terminology Criteria for Adverse Events (CTCAE v4.0). RESULTS: From December 2013 to March 2014, 11 patients (5 men, 6 women) were enrolled. Compliance to the device was high, six patients (55 %) registered timely intake of medication (demonstrating >95 % treatment compliance). Agreement between patients' and clinicians' reported toxicity was substantial for nausea, but discrepant for fatigue, hand-foot syndrome, and mucositis. CONCLUSION: The use of an interactive self-report tool is feasible, reliable, and acceptable to outpatients. The RemeCoach and the algorithm devised will be further developed as an interactive patient-reported outcome (PRO) system, to improve early detection of side effects in an outpatient setting. Further studies are needed to confirm these data and to explore the relationship between optimal patient support and efficacy of treatment.
Authors: Massimo Di Maio; Ciro Gallo; Natasha B Leighl; Maria Carmela Piccirillo; Gennaro Daniele; Francesco Nuzzo; Cesare Gridelli; Vittorio Gebbia; Fortunato Ciardiello; Sabino De Placido; Anna Ceribelli; Adolfo G Favaretto; Andrea de Matteis; Ronald Feld; Charles Butts; Jane Bryce; Simona Signoriello; Alessandro Morabito; Gaetano Rocco; Francesco Perrone Journal: J Clin Oncol Date: 2015-01-26 Impact factor: 44.544
Authors: Claire F Snyder; Neil K Aaronson; Ali K Choucair; Thomas E Elliott; Joanne Greenhalgh; Michele Y Halyard; Rachel Hess; Deborah M Miller; Bryce B Reeve; Maria Santana Journal: Qual Life Res Date: 2011-11-03 Impact factor: 4.147
Authors: T Shirasaka; Y Shimamato; H Ohshimo; M Yamaguchi; T Kato; K Yonekura; M Fukushima Journal: Anticancer Drugs Date: 1996-07 Impact factor: 2.248
Authors: Ethan Basch; Amy P Abernethy; C Daniel Mullins; Bryce B Reeve; Mary Lou Smith; Stephen Joel Coons; Jeff Sloan; Keith Wenzel; Cynthia Chauhan; Wayland Eppard; Elizabeth S Frank; Joseph Lipscomb; Stephen A Raymond; Merianne Spencer; Sean Tunis Journal: J Clin Oncol Date: 2012-10-15 Impact factor: 44.544
Authors: Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag Journal: J Natl Cancer Inst Date: 2009-11-17 Impact factor: 13.506
Authors: Bryce B Reeve; Sandra A Mitchell; Amylou C Dueck; Ethan Basch; David Cella; Carolyn Miller Reilly; Lori M Minasian; Andrea M Denicoff; Ann M O'Mara; Michael J Fisch; Cynthia Chauhan; Neil K Aaronson; Corneel Coens; Deborah Watkins Bruner Journal: J Natl Cancer Inst Date: 2014-07-08 Impact factor: 13.506
Authors: Marc Peeters; Peter van Dam; Marika Anna Rasschaert; Christof Vulsteke; Sven De Keersmaecker; Lieselot Croes; Ilse Van Brussel; Jo Ravelingien; Annelies Janssens; Hans Prenen Journal: ESMO Open Date: 2020-06
Authors: Lorraine Warrington; Kate Absolom; Mark Conner; Ian Kellar; Beverly Clayton; Michael Ayres; Galina Velikova Journal: J Med Internet Res Date: 2019-01-24 Impact factor: 5.428
Authors: William Goodman; Anne-Marie Bagnall; Laura Ashley; Desiree Azizoddin; Felix Muehlensiepen; David Blum; Michael I Bennett; Matthew Allsop Journal: JMIR Cancer Date: 2022-02-17